Funding initiative is dedicated to developing objective biomarkers, or “biological fingerprints,” of Parkinson’s disease.

Project targets glutamate receptor mGluR4 for symptomatic treatment that could replace levodopa, transforming treatment of PD

The Parkinson's Unity Walk is the largest grassroots fundraiser for Parkinson's research in the community. The 14th PUW will be held on Saturday, April 26, 2008, in New York City's Central Park.

Key architect of Foundation’s strategy will build on and expand transformational approach.

The Michael J. Fox Foundation for Parkinson's Research has committed up to $2 million for research toward therapies to alleviate Parkinson's-related cognitive dysfunction and mood disorders. The funding is to be awarded under a new initiative, Cognitive Deficits and Mood Disorders in Parkinson's Disease, made possible by generous leadership funding from Merck Serono (EMD Serono in North America), affiliates of Merck KGaA, Darmstadt, Germany.

Having funded $2 million total to support 27 high-risk, high-reward approaches to Parkinson’s disease research in the first year of its Rapid Response Innovation Awards (RRIA) initiative, The Michael J. Fox Foundation announced that it will commit $2 million to a second round of funding in 2008.

The Michael J. Fox Foundation for Parkinson’s Research today announced approximately $2.5 million in total funding for five clinical research studies under its 2007 Clinical Discovery Program. In keeping with the Foundation’s focus on accelerating scientific solutions that can have a tangible effect on patients’ lives, this annual initiative funds clinical research projects with strong potential to yield new treatments for people living with PD.

The Michael J. Fox Foundation raised a stunning $5.5 million at its gala event, “A Funny (Groovy) Thing Happened on the Way to Cure Parkinson’s,” held Saturday, December 1, at the Sheraton New York.

The Michael J. Fox Foundation raised a stunning $5.5 million at its gala event, “A Funny (Groovy) Thing Happened on the Way to Cure Parkinson’s,” held Saturday, December 1, at the Sheraton New York.

In keeping with The Michael J. Fox Foundation’s mission to accelerate scientific breakthroughs that can transform the lives of people with Parkinson’s disease, the Foundation today announced the appointment of Irene Hegeman Richard, MD, to the newly created role of Senior Medical Advisor.

Click here to see a few minutes of selected clips from Andy Grove's talk at the Society for Neuroscience, November 4, 2007.

The Michael J. Fox Foundation for Parkinson's Research gets it. They have figured out just how many bottlenecks there are for getting good research out of academia and to the patient. And Fox is willing to put its money where it is needed to move along the drug development process.

Michael J. Fox has been named one of 18 "Top Leaders" in America for 2007 in an annual list compiled by U.S. News & World Report and the Center for Public Leadership at Harvard University.

Andrew S. Grove, co-founder of computer chip company Intel, spoke at the annual meeting of the Society for Neuroscience on Sunday, November 4, arguing that the biomedical research enterprise needs a “cultural revolution."  Finding cures for disease, Mr. Grove said, will require different attitudes toward failed experiments, and a major rebalancing of research spending. Read a transcript of his talk here.

MJFF congratulates our Team Fox members, who completed the ING NYC marathon on November 4.

If you're in or around the New York metropolitan area, we need your help on Sunday, November 4!

The Foundation announced the launch of its 2008 Target Validation effort. Under this annual program MJFF will award up to $2 million in 2008 for projects designed to validate the therapeutic potential of scientific discoveries, pushing them one step closer to possible pharmaceutical industry investment and clinical trials.

Writing for Forbes.com, Michael J. Fox discusses how "disruptive philanthropy" can overturn the status quo to help cure Parkinson's and other diseases.

Chemical & Engineering News spoke to Katie Hood, interim CEO of The Michael J. Fox Foundation, about The Bill & Melinda Gates Foundation's new Grand Challenges Explorations program, which bears some structural similarities to MJFF's Rapid Response Innovation Awards initiative launched earlier this year.

Former research team director and key strategy architect to build on Foundation’s momentum in pursuing systemic changes to advance Parkinson’s disease treatments

The Michael J. Fox Foundation for Parkinson’s Research and The New York Academy of Sciences will co-host the first and only major scientific symposium exclusively focused on the development of innovative drugs to target Parkinson’s disease.

The Michael J. Fox Foundation for Parkinson’s Research announced $1.2 million in total awards to four research teams working to advance potentially disease-modifying therapeutic targets for PD along the drug development pipeline. The funding was awarded under the Novel Approaches to Drug Discovery for Parkinson’s Disease program, made possible by generous leadership funding from Elan Corporation, plc (NYSE: ELN), a neuroscience-based biotechnology company.

The Michael J. Fox Foundation for Parkinson’s Research has awarded $2 million total to nine research teams working to validate therapeutic targets for Parkinson’s disease. The awards were made under MJFF’s annual Target Validation initiative, which is designed to accelerate the rate at which new Parkinson’s therapies are brought to market.

Michael J. Fox issued a statement expressing disappointment at this third veto of Mr. Bush's presidency and announcing that he will form Cures and Hope USA, a non-partisan, pro-stem cell educational and political advocacy organization dedicated to building nationwide support for stem cell research.

The Foundation issued a statement in response to the veto and to Michael J. Fox's announcement of his intent to establish a separate 501(c)4 organization, Cures and Hope USA.

The Michael J. Fox Foundation for Parkinson’s Research announced $710,000 in total funding to seven research teams for projects to initially characterize Parkinson’s disease subtypes — distinct forms of the disease that may differ in onset, progression and response to treatment.

MJFF announced the launch of its 2007-2008 Therapeutics Development Initiative, designed to promote industry investment in preclinical research for Parkinson’s disease.

MJFF announced the launch of Critical Challenges in PD, designed to address highly specific questions whose answers are critical to accelerating the development of improved treatments for Parkinson’s disease.

The Michael J. Fox Foundation has announced that, going forward, it will host a conference call question-and-answer session on every funding initiative it launches. The calls will allow researchers to speak directly with Research Programs staff on the specific goals of a program of interest, as well as the types of proposals appropriate for the program.

The Foundation announced that it has awarded $1 million in supplemental funding to five investigators to push forward promising results of work funded under the Foundation’s Community Fast Track 2005 program.

Read a summary of "Overcoming Barriers to Successful Demonstration of Therapeutic Disease Modification," a two-day satellite meeting co-hosted by MJFF and the International Society for CNS Clinical Trials and Methodology (ISCTM) on February 21- 22, 2007. It attracted more than 130 key clinical trial players including academic institutions, pharmaceutical and biotech companies and regulatory agencies.

The first annual Team Fox MVP Awards were held on April 27, 2007. The event honored Team Fox members for their outstanding fundraising efforts in 2006.

The conference, co-hosted by MJFF and The New York Academy of Sciences, will highlight advances in basic and translational research that provide the most current information on scientific discoveries that impact understanding of PD and its treatment.

Prominent speakers including Michael J. Fox and Greg Simon, president of Faster Cures, used the conference as a platform to push the biotech industry for quicker access to cures.

Michael J. Fox urged stakeholders in the drug development process to think strategically about speeding translation of basic science discoveries into patient-relevant disease treatments. Read a transcript of the speech and view selected clips of Mr. Fox at the podium.

By Jay Collins, Boston Herald

The Associated Press reported Monday on Michael J. Fox's appeal to scientists and investors to aggressively translate scientific research into creative treatments for debilitating diseases, including the Parkinson's disease he has fought for more than a decade.

You are invited to attend  "MJFF Strategic Overview: The Michael J. Fox Foundation's Philosophy and Role in Funding Translational Research for Parkinson's Therapies."

Michael J. Fox is one of the "Heroes and Pioneers" included in TIME magazine's list of the 100 most influential people of the year. 

Fox to address biotech leaders on strategy to speed drug development at industry's most important annual conference

Fox to address biotech leaders on strategy to speed drug development at industry’s most important annual conference

The Michael J. Fox Foundation announced the launch of Biomarkers 2007, a two-year, $2-million funding program dedicated to research toward the discovery of an objective biomarker, or "biological fingerprint," of Parkinson’s disease.

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced the launch of its 2007 Clinical Discovery Program.

Sarah Orsay named Chief Executive Officer; Founding CEO Deborah W. Brooks to remain as President and Co-Founder

Science Journal by Sharon Begley, Wall Street Journal

The Therapeutics Development Initiative is a key element in MJFF's strategy to ‘de-risk’ preclinical Parkinson’s disease research for biotech and pharmaceutical companies, thus expanding and catalyzing industry investments in the development of improved PD treatments and a cure.

In work funded by The Michael J. Fox Foundation, scientists have identified a pattern of abnormal functioning in 22 genes that might someday be used in a test to spot people most at risk for Parkinson’s disease.

"Just in time" funding for high-risk, high-reward approaches to PD